Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
MarketMinute.com Stock News
November 08, 2012 at 19:14 PM EST
BioCryst Pharmaceuticals Ends Trial
BioCryst Pharmaceuticals Inc. (
) terminated a Phase 3 trial of its serious influenza treatment peramivir. The stock price plunged 99 cents to close at $1.46.
BioCryst Pharmaceuticals, Inc.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here